Replies to post #453463 on NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

oooooooooohhhhhh.... so this BATON system uses the dendritic cell to load the T cell as it is done in the body with, well, your choice of whatever antigen(s) and/or neoantigen(s)? Is that correct?

Now to the T cell... is it still being engineered, or not? How is it being made, and from what? The DCs come from the patient's leukapheresis... is there a more natural way to "grow" a T cell?

[jondoeuk]

How could targeting neoantigens be better than DCVax which targets all the antigens?

T-cells against oncofetal, cancer-testis, or certain other antigens lack the required affinity and/or specificity to be effective. This is why ADAP (and some other companies) engineer TCRs.

Short answer is, I don’t think it is a better approach than DCVax. But T-cell treatments have been all the rage since the CAR-T treatments Kymriah and Yescarta were approved in 2017, and there is a general belief that T-cell therapy is more effective than a dendritic cell therapy, which hasn’t been proven in clinical trials, or commercially approved (yet). (well other than Provenge and exwannabe’s favorite - Apceden)

In Q4, ADAP should file a BLA for afami-cel [1]. Its first next-gen therapy has shown encouraging activity outside of certain types of STS [2]. A registration-directed PhII testing that is ongoing in esophageal and esophagogastric junction. Another will start in ovarian this year as well. Also, they will test it in combo with an anti-PD-1 and plan on moving an enhanced version forward [3] (both PhI basket trials).

Refs:
1 https://www.globenewswire.com/news-release/2021/11/11/2332690/35803/en/Adaptimmune-Reports-Positive-Results-from-its-Pivotal-SPEARHEAD-1-Trial-in-Patients-with-Synovial-Sarcoma-and-MRCLS-at-CTOS.html
2 https://www.globenewswire.com/news-release/2021/09/13/2295608/35803/en/Adaptimmune-Announces-Clinical-Responses-across-Five-Solid-Tumor-Indications-with-an-Overall-Response-Rate-of-36-and-Promising-Early-Durability-from-its-Next-Generation-SURPASS-Tri.html
3 https://aacrjournals.org/mct/article-abstract/21/1/138/675143/Enhanced-Antitumor-Responses-of-Tumor-Antigen

[jimmy667]

The board today is like kimberlite. Many diamonds. Posts as this one and others from Bio, Senti and others are valuable gems of great value. Thank you all. The BATON system looks like a great technology to expand. Maybe NWBO is too valuable for a buyout and future of cancer treatments look bright. Patience is the order of the months ahead. Thank you all for sharing your knowledge and insights. There has never been anything like this band of posters here.
I am firm belief that NWBO might be the best risk/reward ever in Biotech. I imagine that after TLD NWBO will be inundated with requests from the top researchers throughout the world to collaborated to push all the paradigm shifting technologies of NWBO rapidly forward.

[Kaizenman]

hyperopia: I appreciate the context you have given regarding BATON. I am searching for the reason why this "new" manufacturing method was patented now without any trials ongoing. I have come up with 3 possible reasons:

1) Other organizations are close to patenting something close, and they want to own the IP.

2) Part of the conditions for potentially selling NWBO dictate securing patents surrounding and including the new processes that can be used in conjunction with DCVax.

3) This is signaling intent to pursue a broader treatment approach ahead for the solid cancer space.

My main concern with having a patent w/o associated trials is of course by the time a future trial is complete there will not be much patent life left unless improvements can be made to extend the protection.

Your comment that they could just license the technology to generate cash could be the reason as well.

I am obviously missing a concept here since this move doesn't make sense to me regarding the path outlined for commercializing DCVax-L.

Peace.

[eagle8]

hyperopia,

Thank you for this detailed explanation about the BATON system!
promising technology.

Best to you.

[dmb2]

hyperopia, thx for the science perspectives, it is exciting to see that NWBO and Dr LL have a more comprehensive research program investigating therapy options which will determine therapy enhancements.

The science NWBO has pursued from the jump with DC's being the base tool still appears to be the correct way to utilize the power of nature. Car-T is just a way around DC's in a sense and more typical of BP research.

NWBO has taken the long road but their basic research, headed by Dr LL, will propel oncology into a much more holistic, natural, comprehensive, safer approach with better results. It is reassuring to see NWBO working on their platform to deepen it and to expand it. Their work not only can open more future doors but can also assist in their BLA submission MOA and risk analysis work to RA's.

I am assuming they are at least 1-2 yrs ahead of what we are seeing, maybe more. Their work to connect with other aspects of oncological science can also assist with company connections if they pursue partnership(s).

GLTA